Adial Pharmaceuticals (ADIL) Interest & Investment Income (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Interest & Investment Income of $47059.0 for Q1 2026, down 56.0% sequentially from $106953.0 in Q3 2025, and up 33.14% YoY from $35346.0 in Q1 2025.
Adial Pharmaceuticals (ADIL) Interest & Investment Income (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Interest & Investment Income for 9 years, with the latest figure at $47059.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 33.14% year-over-year to $47059.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $213105.0 (down 9.11% YoY) and the FY2025 annual result came in at $149567.0, down 16.28% from the prior year.
- Interest & Investment Income slipped to $47059.0 in Q1 2026 per ADIL's latest filing, from $106953.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $124901.0 in Q3 2024 and troughed at $3472.0 in Q3 2022.
- A 5-year average of $38586.6 and a median of $26319.5 in 2023 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2023: Interest & Investment Income soared 2072.69% in 2022, then plunged 76.53% in 2023.
- Over 5 years, Interest & Investment Income stood at $47821.0 in 2022, then slumped by 76.53% to $11225.0 in 2023, then surged by 1012.7% to $124901.0 in 2024, then decreased by 14.37% to $106953.0 in 2025, then sank by 56.0% to $47059.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $47059.0, $106953.0, and $23747.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | 58,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47,059.00 |
| Sep 30, 2025 | 106,953.00 |
| Jun 30, 2025 | 23,747.00 |
| Mar 31, 2025 | 35,346.00 |
| Sep 30, 2024 | 124,901.00 |
| Jun 30, 2024 | 51,404.00 |
| Mar 31, 2024 | 22,801.00 |
| Dec 31, 2023 | 11,225.00 |
| Sep 30, 2023 | 10,236.00 |
| Jun 30, 2023 | 19,426.00 |
| Mar 31, 2023 | 28,892.00 |
| Dec 31, 2022 | 47,821.00 |
| Sep 30, 2022 | 3,472.00 |
| Jun 30, 2022 | 6,930.00 |
| Dec 31, 2021 | 2,201.00 |
| Sep 30, 2021 | 2,862.00 |
| Jun 30, 2021 | 1,181.00 |
| Mar 31, 2021 | 295.00 |
| Dec 31, 2020 | 1,349.00 |
| Sep 30, 2020 | 2,532.00 |